A culture of anti-LGBT discrimination could be costing Kenya up to $1.3 billion a year, a new report claims. The report from the pro-LGBT Open for Business coalition sets out the economic case for LGBT+ inclusion in Kenya, after the country’s Supreme Court delayed a much-anticipated ruling on a challenge to anti-gay laws. It is […]
Anti-LGBT discrimination costs Kenya ‘up to $1.3 billion’ a year Read More »
W. David Hardy, MD, adjunct professor of medicine, Johns Hopkins University, discusses the importance of identifying patients with undiagnosed HIV and preventing new infections for accomplishing President Trump’s plan to end the HIV epidemic in 10 years. Transcript During the State of the Union, President Trump announced the ambitious plan for ending the HIV epidemic
HIV-negative men who have sex with men (MSM) living in Vancouver, Canada are redefining ways to negotiate sexual safety and risk, according to qualitative research recently published by Dr Benjamin Klassen and colleagues in BMC Public Health. Condoms are no longer seen as the only means of preventing HIV infection. Biomedical prevention strategies – including
HIV-negative men who have sex with men (MSM) living in Vancouver, Canada are redefining ways to negotiate sexual safety and risk, according to qualitative research recently published by Dr Benjamin Klassen and colleagues in BMC Public Health. Condoms are no longer seen as the only means of preventing HIV infection. Biomedical prevention strategies – including
Antiretroviral therapy (ART) has advanced considerably, from the approval of zidovudine (AZT) in 1987 through the emergence of triple-drug therapy and single-tablet regimens.1,2 Newer agents have fewer adverse effects and provide a life expectancy similar to individuals without HIV infection.3 With clear mortality benefits linked to ART, attention has now turned to the benefits of
Undetectable Equals Untransmittable Read More »
Philadelphia was inching closer to becoming the first city in the United States to open a safe-injection site to address the city’s opioid crisis. But the project has hit a roadblock – the U.S. Department of Justice. Pennsylvania’s top federal prosecutor last week announced he was suing the nonprofit facility called Safehouse – with timing
Future uncertain for city’s safe-injection site Read More »
The kick-off for the Simon Fraser University (SFU) Presidential Dream Colloquium generated much energy and optimism around continued advocacy for individuals living with HIV in Vancouver and across Canada-with the goal in mind of seeing an end to AIDS. However, Dr. Julio Montaner, BC-CfE Executive Director and Physician-in-Chief, warned there is a strong possibility for HIV to see a global resurgence if world leaders become complacent.
International colloquium series focuses on HIV-from cell to society Read More »
World renowned HIV/AIDS researcher and advocate for Treatment as Prevention¨, BC-CfE Executive Director and Physician-in-Chief, UBC University Killam Professor in Medicine,
Dr. Julio Montaner will receive the Senate 150th Anniversary Medal. The BC Centre for Excellence in HIV/AIDS (BC-CfE) at Providence Health Care is proud to announce Dr. Montaner is being recognized for his exemplary leadership and lifelong contribution to improving the health and lives of British Columbians.
Dr. Julio Montaner receives Senate 150th Anniversary Medal Read More »
Vancouver paramedics and firefighters receive a lot of credit for the extra burden they’ve carried since fentanyl arrived in B.C. and sent overdose calls skyrocketing. The same goes for social-service providers and staff at supervised-injection sites. To be sure, they all deserve praise. But there’s another group working to prevent deaths-one that’s a step removed
A Bangkok symposium on HIV/Aids looks at the progress being made to turn the disease from “epidemic” to “endemic” Like most member nations of the United Nations, Thailand has set itself the goal of eliminating new infections of HIV/Aids and reaching “Getting to Zero” by 2030. It is an ambition that faces many challenges. Current
The long road to zero Read More »
The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below
